The FDA on Friday approved AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2-positive solid tumors in adults who have undergone prior systemic treatment and have no alternative treatment options.
Tag Archive for: solid tumors
Genmab on Wednesday announced that it will acquire the privately owned biotech ProfoundBio for $1.8 billion in cash. The deal is meant to help the Danish pharma deepen its cancer pipeline with next-generation antibody-drug conjugate therapies.
After oncology and neuroscience headlined biopharma investment in 2023, experts anticipate increased interest in the autoimmune and obesity spaces this year.
While the company did not provide specific reasons for the halt, Gilead Sciences said it is “reviewing the benefit-risk” of its anti-CD47 antibody magrolimab across all ongoing trials.
Amid falling COVID-19 revenues, Pfizer continues to invest in antibody-drug conjugates in a deal with Nona Biosciences worth $1 billion as its $43 billion Seagen buy closed on Thursday.
The biotech has acquired an exclusive global license for Shanghai-based DualityBio’s investigational antibody-drug conjugate for select solid tumors.
AstraZeneca said on Monday a mid-stage trial of its cancer drug Enhertu showed positive results across multiple HER2-expressing advanced solid tumors in heavily pre-treated patients.
Genome engineering company Replay and The University of Texas’ MD Anderson Cancer Center have joined forces to launch Syena, an oncology product company.
Merck and New Jersey-based Nectin Therapeutics announced a research collaboration agreement Tuesday to study the safety and efficacy of Nectin’s investigational antibody NTX1088 in locally advanced and metastatic solid tumors.
